Opinion|Videos|August 13, 2026
Re-Biopsy Practices and Closing Takeaways
Author(s)Sandip Patel, MD, Chul Kim, MD
The segment discusses consistency of re-biopsy being performed in the clinical setting along with key barriers to obtaining biopsies for patients.
Advertisement
Episodes in this series
The segment discusses consistency of re-biopsy being performed in the clinical setting along with key barriers to obtaining biopsies for patients. The program closes with panelists’ takeaways from the discussion and which emerging data or strategies they are watching most closely.
Advertisement
Related to this article
Pooled results from the phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials confirmed the efficacy of pirtobrutinib in treatment-naive CLL.
Michael J. Morris, MD, discusses the FDA approval of lutetium Lu 177 vipivotide tetraxetan plus an ARPI in PSMA+ mHSPC.
Neoadjuvant PD-1–based immunotherapy plus chemotherapy produced pCRs across three cohorts in resectable locally advanced HNSCC.
A post hoc analysis found similar safety outcomes for fixed-duration regimens containing acalabrutinib/venetoclax across age groups in treatment-naive CLL.
Mayo Clinic researchers identified a protein that cancer cells use to shut down the body's immune response, which may help develop novel cancer treatments.
T-DXd plus pertuzumab was approved in China as first-line treatment for unresectable or metastatic HER2-positive breast cancer.
Topline phase 2a data showed a 48.9% six-month progression-free survival rate with intranasal NEO100 in previously treated IDH1-mutant glioma.
Komal Jhaveri, MD, FACP, discusses the role of CDK4/6 inhibitors for patients with hormone receptor–positive disease and how oral SERD use is changing.
Advertisement
Advertisement
Trending on OncLive
1
T-DXd Plus Pertuzumab Is Approved in China for First-Line HER2+ Metastatic Breast Cancer
2
Intranasal NEO100 Meets Primary End Point in Recurrent IDH1-Mutant High-Grade Glioma
3
Fixed-Duration Acalabrutinib/Venetoclax Regimens Shows Similar Safety Across Age Groups in Treatment-Naive CLL
4
Researchers Discover Immune 'Off Switch' Used by Cancer Cells
5